LGALS9 and myelodysplastic syndrome: There were no significant differences in plasma galectin-9 levels in MDS subtypes according to the World Health Organization (WHO) (Figure 5D) and WHO classification-based Prognostic Scoring System (WPSS) classifications (Figure 5E) [15].